1.0Market Newsdeskhttps://www.marketnewsdesk.comNewsdeskhttps://www.marketnewsdesk.com/index.php/author/newsdesk/rich600338<blockquote class="wp-embedded-content" data-secret="jYF8tDa5vw"><a href="https://www.marketnewsdesk.com/index.php/xortx-appoints-new-director/">XORTX Appoints New Director</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.marketnewsdesk.com/index.php/xortx-appoints-new-director/embed/#?secret=jYF8tDa5vw" width="600" height="338" title="“XORTX Appoints New Director” — Market Newsdesk" data-secret="jYF8tDa5vw" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.marketnewsdesk.com/wp-includes/js/wp-embed.min.js </script> CALGARY, Alberta, July 29, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the appointment of Depesh Narotam to the board of directors as an independent director. Depesh Narotam has been in the financial services industry for over 20 years. He has developed considerable expertise in debt financing, delivering strategic lending solutions to a diverse client base. Over the course of his career Depesh has developed a comprehensive understanding of various sectors specifically the real estate lending landscape where he has been responsible for market expansion and strategic partnerships … Continue reading ""https://www.globenewswire.com/newsroom/ti?nf=OTc5OTk0OSM3NzQ4NDIwIzIwOTcyNzk=